The TARGET-DERM registry longitudinal study highlighted the continued trend of the failure to escalate atopic dermatitis treatments when patients do not meet their therapeutic targets.
Kaitlyn Bader, Assistant Managing Editor
Advertisement
Kaitlyn Bader is the assistant managing editor of Dermatology Times® and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies. Prior to health care news, Kaitlyn worked in digital marketing. She enjoys cooking, reading, and tending to her house plants.
You can reach her at [email protected].
Articles by Kaitlyn Bader, Assistant Managing Editor
This week’s collection of the latest dermatologic studies includes the implementation of an action plan for patients with atopic dermatitis, early childhood eczema and the risk of allergic multicomorbidities, and more.
Advertisement
Advertisement
Advertisement
Trending on Dermatology Times
1
Digital Twins in Dermatology: Your Patient’s Virtual Double Is Coming
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
4
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
5